Navigation Links
Genetic Source of Rare Childhood Cancer Found; Gene is Implicated in Other Cancers
Date:4/19/2009

r-filled lung cysts in the early stage to solid lung tumors in later stages. If detected in the earliest stage, 90 percent of patients appear to be cured when treated with surgery and sometimes chemotherapy. Overall survival drops to about 40 percent if the cancer is diagnosed in the latest stage.

The researchers found that all the children studied with PPB carried damaging mutations in one of their DICER1 genes, giving them one functional and one nonfunctional DICER1 gene in all their body's cells. The researchers indicate that PPB lung tumors probably originate when one or more cells in the lung acquire a harmful mutation in their functional copy of the DICER1 gene.

The researchers also found that PPB lung tumors appear to result from a novel cancer induction mechanism not previously demonstrated. They discovered that loss of DICER1 protein specifically in lung airway cells appears to deregulate signals to nearby cells in which DICER1 itself still functions and somehow causes those cells to transform into malignant cells. However, the cells with the loss of DICER1 do not progress to malignancy.

DICER1 is so-named because its job is to chop up large molecules into smaller control molecules that help regulate the output of many of the 30,000 human genes. The short bits of genetic material it produces during its dicing activities are termed microRNAs.

"Prior research showed that the microRNA profiles of cancer cells are different from those of normal tissue, which pointed toward a possible role for DICER1 in cancer," says senior author Paul Goodfellow, Ph.D., co-director of the Hereditary Cancer Core at the Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital in St. Louis. "Very recently, other research found that reduced DICER1 gene expression in tumor cells is associated with worse outcomes in patients with ovarian, lung, breast and prostate canc
'/>"/>

SOURCE Children's Hospitals and Clinics of Minnesota; Washington University School of Medicine in St. Louis; Children's National Medical Center in Washington, D.C.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Genetics Determine Optimal Drug Dose of Common Anticoagulant
4. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
5. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis
6. Genetic Differences Predict Anti-Inflammatory Benefits From Nutritional Products
7. 454 Sequencing(TM) in Science Today: Researchers Uncover a Genetic Basis for Different Social Behaviors in Wasps
8. deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack
9. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
10. American Fertility Association Calls for Expanded Research to Advance New Technology to Screen Embryos for Genetic Abnormalities
11. Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)... Calif., Dec. 4 Vermillion, Inc. (VRML) (Pink Sheets: VRMLQ) ... Amended Plan of Reorganization and related amended Disclosure Statement with ... ,, A hearing to consider the adequacy of ... with the hearing on the confirmation of the Plan scheduled ...
(Date:12/4/2009)... Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced that ... Principal investigators will discuss the data presentations surrounding carfilzomib ... the 51st American Society of Hematology (ASH) Annual Meeting. ... a.m. ET on Monday, December 7, 2009. The ...
(Date:12/4/2009)... Shared Imaging, LLC, an independent provider of CT, ... hospitals and healthcare providers, is excited to announce ... Ambulatory Health Care, a nationally-recognized, prestigious gold seal ... care. Shared Imaging accreditation is system-wide for its ...
Breaking Medicine Technology:Vermillion Files Amended Plan of Reorganization and Exchanges Debt 2Vermillion Files Amended Plan of Reorganization and Exchanges Debt 3Onyx Pharmaceuticals to Host American Society of Hematology (ASH) Investor Teleconference 2Shared Imaging Earns The Joint Commission's Accreditation for Ambulatory Health Care 2New research program BioInterfaces launched 8742 1New research program BioInterfaces launched 8742 2Quest Diagnostics to Speak at the William Blair 26 Company 29th Annual Growth Stock Conference 48179 1Quest Diagnostics to Speak at the William Blair 26 Company 29th Annual Growth Stock Conference 48179 2Sinovac Begins the Production of Influenza A 28H1N1 29 Vaccine 12524 1Sinovac Begins the Production of Influenza A 28H1N1 29 Vaccine 12524 2Sinovac Begins the Production of Influenza A 28H1N1 29 Vaccine 12524 3
... CAMBRIDGE, Mass., and BERLIN, Sept. 26 ,Genzyme Corporation ... AG, Germany,today announced that the first patient has ... 3 trials examining the safety and efficacy of ... The CARE-MS I trial (Comparison of Alemtuzumab and ...
... 26 Innocoll, Inc., a privately-held,specialty pharmaceutical company, ... clinical development programs and specialty,pharmaceutical operations: - ... in 2007., - GENTAMICIN ... multi-centered clinical trials for the ...
Other Medicine Technology:Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis 2Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis 3Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis 4Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis 5Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis 6Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations 2Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations 3Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations 4Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations 5Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations 6
(Date:12/5/2009)... new three-drug combination has shown in a phase 1/2 ... regimen" in the treatment of patients newly diagnosed with ... bone marrow, say researchers from Dana-Farber Cancer Institute. , ... the 66 patients treated with the drug combination in ... good partial response rate" in the phase 2 population, ...
(Date:12/5/2009)... Blood Cancer Is Most Challenging-- ,, PHILADELPHIA ... identified specific genes, dubbed partner genes, that fuse with ... in infants. By more accurately defining specific partner genes, ... from particular treatments. ,, Oncologists also aim to ...
(Date:12/5/2009)... Midbrook,s advanced Technology Center helps companies develop and test their cleaning ... in a variety of industries and solve problems for customers relating ... ... (Vocus) December 5, 2009 -- Midbrook, Inc , a Jackson, ...
(Date:12/4/2009)... Systems (NYSE: VAR ) announced today that its ... of Stockholders for February 11, 2010 with a record date ... the Crowne Plaza Cabana Hotel, 4290 El Camino Real, Palo ... be webcast by Thomson Financial and can be accessed at ...
(Date:12/4/2009)... Holdings, Ltd (NYSE: AWH ) today announced ... Sennott, Executive Vice,President and Chief Corporate Strategy Officer, will ... Conference being held at the Goldman,Sachs Conference Center in ... About Allied World Assurance Company ...
Breaking Medicine News(10 mins):Health News:Multiple myeloma patients experience high response rate with new 3-drug combination 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 3Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 4Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 2Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 3Health News:Varian Medical Systems Schedules Annual Stockholder Meeting in Palo Alto 2Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2
... MA--The National Institutes of Health (NIH) has awarded one ... 2008 to a team based at Boston University Medical ... (BMC). These awards, together with 12 CTSAs awarded in ... of an NIH effort to build a national consortium ...
... the focus of the Staying Sharp session on June 3 ... recognized series, the program will emphasize successful aging, including how ... future cognitive function; and the importance of clinical trials and ... member Marwan N. Sabbagh will sign copies of his book, ...
... Pa., May 29 The Pennsylvania,Department of Health today ... 31,observance of "World No Tobacco Day," which is designed ... "Exposure to secondhand smoke causes disease and premature death ... Calvin B.,Johnson. "I encourage all Pennsylvania smokers to set ...
... Ensure Patients Receive High-Value Health Care, WASHINGTON, ... care spending and improve the quality of patient ... Insurance Plans (AHIP) was,implemented. PricewaterhouseCoopers reviewed AHIP,s proposals ... fully implemented, the nation,s,total health care expenditures could ...
... Vanessa Carlton to Help ... Cancer Leader, WASHINGTON, May 29 Breast cancer ... Carlton will join Susan G. Komen for the Cure(R) ... activities leading up to the,19th annual Susan G. Komen ...
... Access by Breaking Through Barriers, NEWPORT NEWS, ... Patient Advocate Foundation today announced a strategic,collaboration that ... families,quick access to timely information and specialized patient ... lives of cancer,patients nationwide who are facing access ...
Other Medicine News:Health News:BUMC, BMC receives Clinical and Translational Science Award from NIH 2Health News:AHIP Outlines Plan to Reduce Health Care Costs by $145 Billion 2Health News:AHIP Outlines Plan to Reduce Health Care Costs by $145 Billion 3Health News:AHIP Outlines Plan to Reduce Health Care Costs by $145 Billion 4Health News:Susan G. Komen for the Cure(R) Celebrity Ambassadors to Convene in Nation's Capital to Help Race for the Cure, End Breast Cancer Forever 2Health News:American Cancer Society, Patient Advocate Foundation Announce Free, Personalized Assistance for Cancer Patients 2Health News:American Cancer Society, Patient Advocate Foundation Announce Free, Personalized Assistance for Cancer Patients 3
The Express Plus clinical chemistry analyzer is a fully automated walk away system designed for maximum productivity, convenience and reliability....
Seamlessly integrates with the i2000SR to form a state-of-the-art immunochemistry platform, the ci8200. Flexibility to prioritize STAT, automated rerun/dilution, and reflex testing over routines to e...
... and controls interchangeable with other Roche/Hitachi ... training costs. Consistent patient results throughout ... handling. 70 positions for routine, STAT ... volumes. Intermix sample types. Intermix 5 ...
Modular Pre-Analytics is an integral component of the new modular systems platform which combines pre-analytics, clinical chemistry and immunochemistry....
Medicine Products: